** Shares of drug developer Arvinas ARVN.O fall 5.6% to $6.19, hitting all-time low
** Piper Sandler reduces price target to $24 from $67 on narrowed Vepdegestrant ESR1-mutant mBC approval; remains "overweight"
** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last month
** Vepdegestrant only helped to extend progression-free survival in a subgroup of participants with a specific gene mutation, the company said in March
** ARVN is developing PROteolysis TArgeting Chimeras (PROTACs), which is a technique for the selective degradation of target proteins
** PROTACs are novel technology never tested in man that may fail in the clinic; ARVN's partnerships may falter and it may require additional capital - Piper Sandler
** Up to last close, stock had fallen nearly 66% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.